Home » Authors » Kim Coghill

Kim Coghill

Articles

ARTICLES

ImClone, BMS File New BLA Seeking Approval Of Erbitux

Aug. 15, 2003

Minus the Waksal brothers, ImClone Systems Inc. and Bristol-Myers Squibb Co. forged ahead and, as planned, filed a biologics license application for the investigational IgG1 monoclonal antibody Erbitux for metastatic colorectal cancer. (BioWorld Today)

ImClone, BMS File New BLA Seeking Approval Of Erbitux

Aug. 15, 2003

Minus the Waksal brothers, ImClone Systems Inc. and Bristol-Myers Squibb Co. forged ahead and, as planned, filed a biologics license application for the investigational IgG1 monoclonal antibody Erbitux for metastatic colorectal cancer. (BioWorld Today)

NIH Grant Of $35M Fueling Extensive Study Of Lipids

Aug. 14, 2003

NIH Grant Of $35M Fueling Extensive Study Of Lipids

Aug. 14, 2003

FDA Rule That Limits Patent Stacking Set To Go Into Effect

Aug. 13, 2003

FDA Rule That Limits Patent Stacking Set To Go Into Effect

Aug. 13, 2003

ViroPharma Licenses CMV Drug From Glaxo For $3.5M Up Front

Aug. 12, 2003

ViroPharma Licenses CMV Drug From Glaxo For $3.5M Up Front

Aug. 12, 2003

Pfizer Joins Effort To Limit Sales Of Drugs From Canada

Aug. 11, 2003

Pfizer Joins Effort To Limit Sales Of Drugs From Canada

Aug. 11, 2003

View All Articles by Kim Coghill

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 17, 2026.
AAIC 2026: Age of amyloid is being joined by time of tau
BioWorld
The Alzheimer’s Association International Conference (AAIC) is the world’s biggest dementia conference. And at the AAIC 2026 meeting, there is big buzz around...
Celia trial: data strong, analysts skeptical
BioWorld
Tuesday brought what was arguably the most anticipated presentation of the 2026 Alzheimer’s Association International Conference when Catherine Mummery, head of...
News in brief
BioWorld Asia
BioWorld Asia briefs for July 14, 2026
Voyager’s gene therapy reduces tau levels in AD models
BioWorld Science
At the Alzheimer’s Association International Conference, researchers from Voyager Therapeutics Inc. presented preclinical efficacy data for VY-1706, a blood-brain...